3rd Quarter - Report

OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.

Firm
Client
Income
—
Expenses
$350,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare Part D, 42 CFR Part 2 (CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS) Polycystic Kidney Disease,Mental Health

LobbyistCovered position, as disclosed
ORKIDEH MALKOC —
MOLLY RYAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Medicare/Medicaid MMM

Medicare Part D Redesign, Drug Pricing (H.R.3, SFC bill PDPRA)

LobbyistCovered position, as disclosed
ORKIDEH MALKOC —

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.